Par Drugs and Chemicals LimitedQ2 FY27 Results & Financial Update
Par Drugs and Chemicals Limited: Q2 FY27 standalone results and company financials – revenue ₹27.43 Cr, PAT ₹2.63 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Par Drugs and Chemicals price & chart
Market price₹125.80
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Par Drugs and Chemicals Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Par Drugs and Chemicals Limited reported revenue from operations of INR 27.43 crore for the quarter ended September 30, 2026, marking a sequential decrease compared to the preceding quarter ended June 30, 2026.
Total income for Q2 FY27 stood at INR 27.43 crore, reflecting a moderation in top-line contribution from non-operating streams such as other income, which dropped sharply during the period.
Profit before tax (PBT) for the quarter came in at INR 3.54 crore, while profit after tax (PAT) stood at INR 2.62 crore, translating to a basic and diluted earnings per share (EPS) of INR 2.14 for the unannualised period.
The sequential contraction in profitability was influenced by higher material consumption costs and inventory adjustments, alongside a normalization in other income relative to the previous quarter.
The company's total expenses for the quarter amounted to INR 23.89 crore, driven primarily by raw material consumption of INR 13.28 crore and other expenses of INR 8.82 crore.
Tax expenses for Q2 FY27 were recorded at INR 0.92 crore, reflecting standard statutory provisions on earnings for the standalone entity.
01 · Business model
What does Par Drugs and Chemicals do?
Par Drugs and Chemicals Limited is engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), operating out of Gujarat, India.
The company's operational model focuses on specialized API manufacturing, serving pharmaceutical formulation makers across domestic and international markets.
Par Drugs operates as a standalone entity with no subsidiaries, joint ventures, or associates, concentrating its entire operational footprint on a single business segment under Ind AS 108.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹27.43 Cr | ₹31.28 Cr |
| Total income | ₹27.43 Cr | ₹32.22 Cr |
| Profit before tax | ₹3.54 Cr | ₹6.33 Cr |
| Profit after tax | ₹2.63 Cr | ₹4.71 Cr |
| EPS | ₹2.14 | ₹3.83 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 9.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 12.9% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations of INR 27.43 crore was generated entirely from the company's core manufacturing activity within its single API business segment.
What drove margins
Cost of materials consumed stood at INR 13.28 crore, representing the single largest expenditure category for the quarter.
Changes in inventories of finished goods, stock-in-trade, and work-in-progress showed a positive adjustment of INR 0.65 crore.
Employee benefits expense was reported at INR 1.48 crore, while finance costs remained minimal at INR 0.02 crore.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates primarily in the manufacturing of APIs, which constitutes a single business segment under Ind AS 108.
05 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
Capital work-in-progress stood at zero as of September 30, 2026, compared to INR 0.72 crore as of March 31, 2026, indicating the capitalization or completion of prior outlays.
06 · Reported developments
What changed operationally
The company continues to maintain a debt-free balance sheet with no borrowings across non-current or current liabilities.
07 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash generated from operating activities for the half year ended September 30, 2026, was INR 2.34 crore after accounting for income tax payments of INR 2.24 crore.
Trade receivables increased significantly to INR 22.95 crore as of September 30, 2026, compared to INR 12.03 crore at the end of March 2026.
Capital allocation & funding
The company maintained zero long-term and short-term debt borrowings on its balance sheet as of September 30, 2026.
08 · Beyond the numbers
What changed beyond the numbers
Reported update
Investor Grievances
The Board took note of the investor grievances report for the quarter ended September 30, 2026, noting zero pending or unresolved complaints on SEBI's SCORES platform.
09 · Key Q&A
The quarter, answered directly
What does Par Drugs and Chemicals do?
Par Drugs and Chemicals Limited is engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), operating out of Gujarat, India.
What is the clearest takeaway from Q2 FY27?
Par Drugs and Chemicals Limited reported revenue from operations of INR 27.43 crore for the quarter ended September 30, 2026, marking a sequential decrease compared to the preceding quarter ended June 30, 2026.
What drove revenue or demand?
Revenue from operations of INR 27.43 crore was generated entirely from the company's core manufacturing activity within its single API business segment.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 13.28 crore, representing the single largest expenditure category for the quarter.
What changed operationally beyond the headline numbers?
Capital work-in-progress stood at zero as of September 30, 2026, compared to INR 0.72 crore as of March 31, 2026, indicating the capitalization or completion of prior outlays.
What should the next disclosure help confirm?
Monitor the evolution of trade receivables and inventory levels following the notable increase in receivables during the first half of the financial year.
10 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
11 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Working Capital Cycle: Monitor the evolution of trade receivables and inventory levels following the notable increase in receivables during the first half of the financial year.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.